SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Laura M. Kulik, Attasit Chokechanachaisakul, Evaluation and Management of Hepatocellular Carcinoma, Clinics in Liver Disease, 2015, 19, 1, 23

    CrossRef

  2. 2
    Julius Chapiro, Rafael Duran, MingDe Lin, Rüdiger E. Schernthaner, Zhijun Wang, Boris Gorodetski, Jean-François Geschwind, Identifying Staging Markers for Hepatocellular Carcinoma before Transarterial Chemoembolization: Comparison of Three-dimensional Quantitative versus Non–three-dimensional Imaging Markers, Radiology, 2015, 275, 2, 438

    CrossRef

  3. 3
    Nima Kokabi, Juan C. Camacho, Minzhi Xing, Faramarz Edalat, Pardeep K. Mittal, Hyun S. Kim, Immediate post-doxorubicin drug-eluting beads chemoembolization Mr Apparent diffusion coefficient quantification predicts response in unresectable hepatocellular carcinoma: A pilot study, Journal of Magnetic Resonance Imaging, 2015, 42, 1
  4. 4
    Arun Chockalingam, Rafael Duran, Jae Ho Sohn, Rüdiger Schernthaner, Julius Chapiro, Howard Lee, Sonia Sahu, Sonny Nguyen, Jean-François Geschwind, MingDe Lin, Radiologic-pathologic analysis of quantitative 3D tumour enhancement on contrast-enhanced MR imaging: a study of ROI placement, European Radiology, 2015,

    CrossRef

  5. 5
    Adeel R. Seyal, Fernanda D. Gonzalez-Guindalini, Atilla Arslanoglu, Carla B. Harmath, Robert J. Lewandowski, Riad Salem, Vahid Yaghmai, Reproducibility of mRECIST in assessing response to transarterial radioembolization therapy in hepatocellular carcinoma, Hepatology, 2015, 62, 1
  6. 6
    Aparna Kalyan, Halla Nimeiri, Laura Kulik, Systemic Therapy of Hepatocellular Carcinoma, Clinics in Liver Disease, 2015, 19, 2, 421

    CrossRef

  7. 7
    Michael Vouche, Riad Salem, Frank H. Miller, Marc Lemort, Bruno Vanderlinden, Daniel De Becker, Alain Hendlisz, Patrick Flamen, Y90 radioembolization of colorectal cancer liver metastases: response assessment by contrast-enhanced computed tomography with or without PET-CT guidance, Clinical Imaging, 2015, 39, 3, 454

    CrossRef

  8. 8
    Tushar Patel, Denise Harnois, Assessment of response to therapy in hepatocellular carcinoma, Annals of Medicine, 2014, 46, 3, 130

    CrossRef

  9. 9
    Julius Chapiro, Rafael Duran, Jean-François Geschwind, Combination of intra-arterial therapies and sorafenib: Is there a clinical benefit?, La radiologia medica, 2014, 119, 7, 476

    CrossRef

  10. 10
    Derek M Manas, Hypertrophy in the contralateral lobe post-selective internal radiation therapy, Future Oncology, 2014, 10, 15s, 65

    CrossRef

  11. 11
    Laura Kulik, Michael Vouche, Sean Koppe, Robert J. Lewandowski, Mary F. Mulcahy, Daniel Ganger, Ali Habib, Jennifer Karp, Patrice Al-Saden, Mario Lacouture, Jonathan Cotliar, Michael Abecassis, Talia Baker, Riad Salem, Prospective randomized pilot study of Y90+/−sorafenib as bridge to transplantation in hepatocellular carcinoma, Journal of Hepatology, 2014, 61, 2, 309

    CrossRef

  12. 12
    Julius Chapiro, Laura D. Wood, MingDe Lin, Rafael Duran, Toby Cornish, David Lesage, Vivek Charu, Rüdiger Schernthaner, Zhijun Wang, Vania Tacher, Lynn Jeanette Savic, Ihab R. Kamel, Jean-François Geschwind, Radiologic-Pathologic Analysis of Contrast-enhanced and Diffusion-weighted MR Imaging in Patients with HCC after TACE: Diagnostic Accuracy of 3D Quantitative Image Analysis, Radiology, 2014, 273, 3, 746

    CrossRef

  13. 13
    Daniel Shouval, The emerging questionable benefit of sorafenib as a neo-adjuvant in HCC patients treated with Y-90 radioembolization pending liver transplantation, Journal of Hepatology, 2014, 61, 2, 190

    CrossRef